Fig. 14

The development direction of small molecules targeting m⁶A regulators. Build compound libraries based on CADD, drug design, drug repurposing, DNA-Encoded Libraries (DELs) and natural products. Compounds can then be screened for potential new targets (eg. multiple targets targeting FTO simultaneously, targeting interactions between MTCs, targeting other less studied m⁶A regulators), and then applying PROTAC, ABPP, TPP, ferroptosis, ICI and other technologies or mechanisms to optimize compounds. Finally, the druggability of compounds should be improved as much as possible